Roche Accutane Exhibit Hall Response On Psychosis Risk Draws FDA Letter

Roche's response to a question about Accutane-associated psychosis asked at the company's exhibit booth during the American Pharmaceutical Association annual meeting minimizes the drug's risk of psychiatric disorders, an FDA ad division letter says